Trial Profile
Twenty-Four-Hour Plasma Glucose Profiles Observed in Patients With Type 2 Diabetes During Therapy Consisting of Oral Agent(s) Plus Twice-Daily Insulin Lispro Low Mixture or Once-Daily Insulin Glargine
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin neutral protamine lispro/insulin lispro (Primary) ; Antihyperglycaemics; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 29 Aug 2012 Planned number of patients changed to 15.
- 29 Aug 2012 Status changed from not stated to completed.
- 05 Nov 2010 New trial record.